Replies to post #129997 on Biotech Values

[DewDiligence]

EXEL—Unless the company is a total fraud as DD likes to imply…

I implied no such thing.

[jq1234]

But there was something interesting in the release that almost everyone is overlooking (at least in public discussions), namely that 306 and 307 will use a 60mg dose.

I discussed it here, but no one else picked it up until now.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68532176

The answer for using 60mg dose is, many patients in RDT trial used dose reduction to 60mg, that showed no adverse effect on efficacy. 40mg and lower dose is more for earlier stage of PC to me.

In the MTC trial the dosing started at 175mg with ugly side effects

No, MTC trial used 125mg QD. Original MTD was 175mg which obviously wasn't well done, but realized it wasn't well tolerated during GBM trial, thus dose reduced to 125mg.

[biomaven0]

>EXEL

60mg dose

Yes, I noticed that, particularly in the context of their reference in today's call to the not-yet-public Smith data. That's what made me wonder if this decision to go ahead now with the trial absent FDA buy-in is actually a sign of confidence.

Peter